Psilocybin for Alcohol Use Disorder: Clinical Trial Results
Alcohol use disorder (AUD) kills approximately 95,000 Americans per year and is one of the most costly and treatment-resistant conditions in medicine. Existing medications (naltrexone, acamprosate, disulfiram) have modest efficacy. The 2022 JAMA Psychiatry trial changed the conversation.
The 2022 JAMA Psychiatry Trial
Researchers at NYU and UCSF randomized 93 adults with alcohol use disorder to receive either two psilocybin sessions (25–40mg) or antihistamine (active placebo), both combined with psychotherapy. The primary outcome was percentage of heavy drinking days.
Results: The psilocybin group reduced heavy drinking days from 52% to 10% of days at 8-month follow-up. The placebo group reduced from 52% to 24%. The difference was statistically significant and clinically meaningful. 48% of psilocybin participants achieved total abstinence at 8 months, compared to 24% for placebo.
Why These Results Are Remarkable
To put these numbers in context: naltrexone (the most effective FDA-approved medication for AUD) reduces heavy drinking days by approximately 25% compared to placebo. Psilocybin produced a 50%+ reduction. These are among the strongest results ever seen in addiction medicine.
The Mechanism
Alcohol addiction involves hyperactivated reward circuits and impaired prefrontal control over craving. Psilocybin addresses both: it reduces reward circuit hyperactivity and enhances prefrontal regulation. The "mystical experience" quality of psilocybin sessions also produces profound shifts in values and identity that support sustained sobriety.